CHITA – a registry of in vitro NAMs
Tips for biologists who want to improve their data skills Biologists can play a key role in implementing FAIR (Findable, Accessible, Interoperable and Resusable) data – here are easy steps…
Many drugs can cause adverse effects on the cardiovascular system. Oncology drugs including targeted kinase inhibitors are particularly problematic. Cardiovascular toxicities present in the clinic as high blood pressure, cardiac…
The ToxCast program of the US EPA was initiated over a decade ago. Its goal was to find rapid and efficient methods to prioritize thousands of chemicals for potential human health…
Excipients are the “fillers” in formulated drugs. They are included to ensure long term storage, stabilize or promote delivery of the active drug. Excipients are assumed by many to be…
Phenotypic assays using human cell types can help replace animal testing in drug discovery and product development. We can’t trust these assays, however, if we can’t explain why or why…
Biology and engineering – my favorite topic! Thank you to Vijay Pande and Derek Lowe for recent blog posts discussing the influence of engineering in biology research and drug discovery. I believe…
The recent failure of the IDO inhibitor epacadostat in combination with Merck’s pembrolizumab for immuno-oncology (IO) has been the subject of numerous reports and commentary (see here, here, here and Vinay Prasad’s epic twitter rant here). And now today…
Machine learning & artificial intelligence (AI) is the latest new new thing capturing interest in the pharmaceutical industry. Predicting patient responses from large data sets gathered by wearable devices or…
The Alto Predict Project is an open science project to organize our knowledge of the causal mechanisms underlying drug effects on human outcomes at the cell and pathway level. This…
This new article in DDW adds to some very good recent perspectives on phenotypic drug discovery (PDD) from the pharma industry in NRDD and ADDT (see additional articles and further…
